EVOGENE LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 244.3 ILa | +1.33% |
|
+3.52% | -18.51% |
| May. 23 | Earnings Flash (EVGN) EVOGENE Posts Q1 Revenue $4.2M, vs. Street Est of $3.5M | MT |
| May. 23 | Evogene Ltd. Provides Revenue Guidance for the Year 2024 | CI |
| Sales 2024 * | 14.99M 5.64B | Sales 2025 * | 25.85M 9.72B | Capitalization | 32.39M 12.18B |
|---|---|---|---|---|---|
| Net income 2024 * | -22M -8.27B | Net income 2025 * | -19M -7.14B | EV / Sales 2024 * | 2.16 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.25 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 142 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.34% |
More Fundamentals
* Assessed data
More news
Latest transcript on Evogene Ltd.
More press releases
| 1 day | +1.33% | ||
| 1 week | +3.52% | ||
| Current month | +0.45% | ||
| 1 month | -9.79% | ||
| 3 months | -14.91% | ||
| 6 months | -26.66% | ||
| Current year | -18.51% |
1 week
231.40
246.00
1 month
225.00276.00
Current year
225.00370.00
1 year
189.30610.40
3 years
189.301 161.00
5 years
189.303 350.00
10 years
189.305 450.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ofer Haviv
CEO | Chief Executive Officer | 58 | 01-12-31 |
Yaron Eldad
DFI | Director of Finance/CFO | 57 | 22-03-31 |
Mark Kapel
CTO | Chief Tech/Sci/R&D Officer | 48 | 04-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dan Falk
BRD | Director/Board Member | 79 | 21-11-16 |
Sarit Firon
CHM | Chairman | 58 | 16-08-10 |
Leon Recanati
BRD | Director/Board Member | 76 | 05-04-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-03 | 244.3 | +1.33% | 13 187 |
| 24-07-02 | 241.1 | -0.21% | 75,608 |
| 24-07-01 | 241.6 | -0.66% | 7,069 |
| 24-06-30 | 243.2 | +2.01% | 53,115 |
| 24-06-27 | 238.4 | +1.02% | 40,381 |
Delayed Quote TEL AVIV STOCK EXCHANGE, July 03, 2024 at 07:15 am EDT
More quotes
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Calendar
2024-08-06
- Q2 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -18.51% | 32.39M | |
| +17.72% | 44.87B | |
| -10.33% | 37.8B | |
| +42.32% | 37.61B | |
| +29.36% | 31.32B | |
| -8.44% | 27.4B | |
| +12.45% | 26.32B | |
| +44.19% | 14.07B | |
| +31.93% | 12.5B | |
| -7.67% | 11.23B |
- Stock Market
- Equities
- EVGN Stock
